Tumor immunotherapy by vaccination with cytokine gene transfected cells

International Reviews of Immunology

Volumn 14, Issue 2-3, 1997, Pages 193-212

  Viret, Christophe ^a   Lindemann, Albrecht ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cytokines; Gene transfer; Immunotherapy; Tumor; Vaccine

Indexed keywords

EID: 0030972553     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189709116852     Document Type: Review

References (88)

1. Boon, T., Cerottini, J.C., Van Den Eynde, B., Van Der Bruggen, P., Van Pel, A. Tumor antigens recognized by T lymphocytes. An. Rev. Immunol. 12, 337-65, 1994.
2. Hewitt, H., Blake, E., Walder, A. A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br. J. Cancer 33, 241-59, 1976.
3. Boon, T., Kellerman, O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl. Acad. Sci. USA 74, 272-75, 1977.
4. Boon, T., Van Pel, A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants and against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA 74, 1519-1523, 1978.
5. Van Pel, A., Vessiere, F., Boon, T. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J. Exp. Med. 157, 1992-2001, 1983.
6. Van Pel, A., Van Der Bruggen, P., Coulie, P.G., Brichard, V., Lethe, B., Van Den Eynde, B., Uyttenhove, C., Renauld, J.C., Boon, T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunological Reviews 145, 229-50, 1995.
7. Lindenmann, J. Immunity to transplantable tumors following viral oncolysis. Mechanism of immunity to Ehrlich ascites tumor. J. Immunol. 92, 912-919, 1964.
8. Lindenmann, J., Klein, P.A. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93-108, 1967.
9. Kobayashi, H., Sendo, F., Shirai, T., Kaji, H., Kodama, T., Saito, H. Modification in growth of transplantable rat tumors exposed to friend virus. J. Natl. Cancer Inst. 42, 413-19, 1969.
10. Fearon, E., Itaya, T., Hunt, B., Vogelstein, B., Frost, P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48, 2975-80, 1988.
11. Colombo, M.P., Modesti, A., Parmiani, G., Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocytes cross-talk. Cancer Res. 52, 4853-57, 1992.
12. Bubenik, J., Voitenok, N.M., Kieler, J., Prassolov, V., Chumakov, P.M., Bubenikova, D., Simova, J., Jandlova. T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol. Lett. 19, 279-82, 1988.
13. Bubenik, J., Simova, J., Jandlova, T. Immunotherapy of cancer using local administration of lymphoid cells expression IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23, 287-92, 1990.
14. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simon, J.W., Karasuyama, JH., Vogelstein, B., Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403, 1990.
15. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., Gilboa, E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-24, 1990a.
16. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K , Gilboa, E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res. 50, 7820-25, 1990.
17. Ley, V., Roth, C., Langlade-Demoyen, P., Larsson-Sciard, E.L., Kourilsky, P. A novel approach to the induction of specific cytolytic T cells in vivo. Res. Immunol. 141, 855-63, 1990.
18. Ley, V., Langlade-Demoyen, P., Kourilsky, P., Larsson-Sciard, E.L. Interleukin-2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 21, 851-54, 1991.
19. Russel, S.J., Eccles, S.A., Fleming, C.L., Johnson, C.A., Collins, M.K.L. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J Cancer 47, 244-51, 1991.
20. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., Mulligan, R. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-43, 1993.
21. Schmidt, W., Schweighoffer, T., Herbst, E., Maass, G., Berger, M., Schilcher, F., Schaffner, G., Birnstiel, M.L. Cancer vaccines: the interleukin-2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-14, 1995.
22. Sobol, R.E., Royston, I., Fakhrai, H., Shawler, D.L., Carson, C., Dorigo, O., Gjerset, R., Gold, D.P., Kozio, J., Mercola, D. Injection of colon carcinoma patients with irradiated tumor cells and fibroblasts genetically modified to secrete IL-2 (IL2): a phase-1 study. Human Gene Therapy 6, 195-205, 1995.
23. + T lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149, 3627-35, 1992.
24. Hock, H., Dorsch, M., Kuzendorf, U., Qin, Z., Diamantstein, T., Blankenstein, T. Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-g. Proc. Natl. Acad. Sci. USA 90, 2774-8, 1993.
25. Pulaski, B.A., McAdam, A.J., Hutter, E.K., Biggar, S., Lord, E.M., Frelinger, J.G. Interleukin-3 enhances development of tumor-reactive cytotoxic T cells by a CD4-dependent mechanism. Cancer Res. 53, 2112-17, 1993.
26. Roth, C., Mir, L.M., Cressent, M., Quintin-Colonna, F., Ley, V., Fradelizi, D., Kourilsky, P. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int. Immunol. 4, 1429-36, 1992.
27. Tepper, R.I., Pattengale, P.K., Leder, P. Murine interleukin-4 displays potent anti-activity in vivo. Cell 57, 503-12, 1989.
28. Li, W., Diamanstein, T., Blankenstein, T. Lack of tumorigenicity of interleukin-4 autocrine growing cells seems related to the anti-tumor function of interleukin-4. Mol. Immunol. 27, 1331-7, 1990.
29. Blankenstein, T., Li, W., Muller, W., Diamanstein, T. Retroviral interleukin-4 gene transfer into interleukin-4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur. J. Immunol. 20, 935-8, 1990.
30. Golumbek, P., Lazenby, A., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., Pardoll, D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-16, 1991.
31. Tepper, R.I., Coffman, R.L., Leder, P. An eosinophil-dependent mechanism for the antitumor effect of IL-4. Science 257, 548-551, 1992.
32. Yu, J.S., Wei, M.X., Chiocca, E.A., Martuza, R.L., Tepper, R.I. Treatment of glioma by engineered interleukin-4 secreting cells. Cancer Res. 53, 3125-8, 1993.
33. Crawford, R.M., Finbloom, D.S., O'Hara, J., Paul, W.E., Meltzer, M.S. B cell stimulatory factor-1 (Interleukin-4) activates macrophages for increased tumoricidal activity and expression of 1a antigens. J. Immunol. 139, 135-41, 1987.
34. Thornill, M.H., Wellicome, S.M., Mahiouz, D.L., Lanchbury, J.S.S., Kyan-Aung, U., Haskard, D.O. Tumor necrosis factor combines with IL-4 or IFN-g to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent binding mechanisms. J. Immunol. 146, 592-98, 1991.
35. Lebel-Binay, S., Laguerre, B., Quintin-Colonna, F., Conjeaud, H., Magazin, M., Miloux, B., Pecceu, F., Ferrara, P., Fradelizi, D. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur. J. Immunol. 25, 2340-8, 1995.
36. + T cell-dependent tumor rejection. J. Exp. Med. 174, 1291-8, 1991.
37. Mc Bride, W.H., Thacker, J.D., Comora, S., Economou, J.S., Kelley, D., Hodge, D., Dubinett, S.M., Dougherty, G.J. Genetic modification of a murine fibrosarcoma to produce interleukin-7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52, 3931-3937, 1992.
38. Jicha, D.L., Mule, J.J., Rosenberg, S.A. Interleukin-7 generates anti-tumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174, 1511-15, 1991.
39. Aoki, T., Tashiro, K., Miyatake, S., Kinash, T., Nakano, T., Oda, Y., Kikuchi, H , Honjo, T. Expression of murine interleukin-7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89, 3850-54, 1992.
40. Cayeux, S., Beck, C., Aicher, A., Dorken, B., Blankenstein, T. Tunor cells cotransfected with interleukin-7 and B7-1 genes induce CD25 and CD28 tumor-infiltrating T lymphocytes and are strong vaccines. Eur J. Immunol. 25, 2325-2331, 1995.
41. Martinotti, A., Stoppacciaro, A., Vagliani, M., Melani, C., Spreafico, F., Wysocka, M., Parmiani, G., Trinchieri, G., Colombo, M.P. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25, 137-46, 1995.
42. Tahara, H., Zitvogel, L., Storkus, W.J., Zeh, H.J., McKinney, T.G., Schreiber, R.D., Gubler, U., Robbins, P.D., Lotze, M.T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154, 6466-74, 1995
43. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., Sakata, T. Exogenous expression of mouse interferon-g cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 86, 9456-60, 1989.
44. Teramura, Y., Watanabe, Y., Kan, N., Masuda, T., Kuribayashi, K. Interferon-g-producing tumor induces host tumor-specific T cell responses. Jpn. J. Cancer. Res. 84, 689-96, 1993
45. Yanagihara, K., Seyama, T., Watanabe, Y. Anti-tumor potential of interferon-g, retroviral expression of mouse interferon-g cDNA in two kinds of highly metastatic mouse tumor line reduces their tumorigenicity. Natl. Imm. 13, 102-112, 1994.
46. Restifo, N.P., Spiess, P.J., Karp, S.E., Mule, J., Rosenberg, S.A. A non immunogenic sarcoma transduced with the cDNA for interferon-g elicits CD8+ cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175, 1423-31, 1992.
47. Porgador, A., Bannerji, R., Watanabe, Y., Feldman, M., Gilboa, E., Eisenbach, L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-g gene-inserted tumor cells. J. Immunol. 150, 1458-70, 1993.
48. Klavinskis, L.S., Geckeler, R., Oldstone, M.B. Cytotoxic T lymphocyte control of acute lymphocytic choriomenigitis virus infection, interferon gamma, but not tumor necrosis factor alpha, displays antiviral activity in vivo. J. Gen. Virol. 70, 3317-25, 1989.
49. Herberman, R.B., Ortaldo, J.R., Montivani, A., Hobbs, D.S., Kung, H.F., Pestka, S. Effekt of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol. 67, 160-68, 1982.
50. Rosenthal, F.M., Cronin, K., Bannerji, R., Golde, D.W., Gansbacher, B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 83, 1289-98, 1994.
51. Ferrantini, M., Proietti, E., Santodonato, L., Gabriele, L., Peretti, M., Plavec, I., Meyer, F., Kaido, T., Gresser, I., Belardelli, F. a-1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice, anti-tumor therapy by means of interferon-producing cells. Cancer Res. 53, 1107-12, 1993.
52. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666, 1975.
53. Beutler, B., Cerami, A. The biology of cachectin/TNF: a primary mediator of the host response. Annu. Rev. Immunol. 7, 625, 1989.
54. Gamm, H., Lindemann, A., Mertelsmann, R., Herrmann, F. Phase I clinical trial of recombinant human tumor necrosis factor alpha in patients with advanced malignancy Eur. J. Cancer. 27, 856-863, 1991.
55. Asher, A.L., Mulé, J.J., Kasid, A., Restifo, N.P., Salo, J.C., Reichert, C.M., Jaffe, G., Fendly, B., Kriegler, M., Rosenberg, S.A. Murine tumor cells transduced with the gene for tumor necrosis factor-α J. Immunol. 146, 3227-3234, 1991.
56. Karp, S.E., Farber, A., Salo, J.C., Hwu, P., Jaffe, G., Asher, A.L., Shiuloni, E., Restifo, N.P., Mulé, J.J., Rosenberg, S.A. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J. Immunol. 150, 896-908, 1993.
57. Marincola, F.M., Ettinghausen, S., Cohen, P.A., Cheshire, L.B., Restifo, N.P., Mulé, J.J., Rosenberg, S.A. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly ikmmunogenic tumor engineered to secrete human TNF-α Am. Ass. Immunol. 3500-3503, 1994.
58. Zhihai, Q., Krüger-Krasakages, S., Kunzendorf, U., Hock, H., Diamantstein, T., Blankenstein, T. Expession of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med. 178, 355-360, 1993.
59. Weaver, C.T., Duncan, L.M., Unanue, E.R. T cell induction of macrophage IL-1 during antigen presentation. J. Immunol. 142, 3469-3476, 1989.
60. Mc Cune, C.S., Marquis, D.M. Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res. 50, 1212-1215, 1990.
61. Apte, R.N., Douvdevani, A., Huleihel, M., Fima, E., Hacham, M., Shimoni, N., Dvorkin, T., Segal, S. IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcomas. Folia. Biol. 38, 240-257, 1992.
62. Douvdevani. A., Huleihel, M., Zoller, M., Segal, S., Apte, R.N. Reduced tumor-igenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer. Int. J. Canc. 51, 822-830, 1992.
63. Dougherty, G.J., Thacker, J.D., Lavey, R.S., Belldegrun, A. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Canc. Immunol. Immunother. 38 ,339-345, 1994.
64. Sun, W.H., Burkholder, J.K., Sun, J., Culp, J., Turner, J., Lu, X.G., Pugh, T.D., Ershler, W.B., Yang, N.S. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. PN AS USA 92, 2889-2893, 1995.
65. Botazzi, B., Walter, S., Govoni, D., Colotta, F., Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285, 1992.
66. Laning, J., Kawasaki, H., Tanaka, E., Luo, Y., Dorf, M.E. Inhibition of in vivo tumor growth by the β chemokine, TCA3′. Amer. Assoc. Immunol. 4625-4635, 1994.
67. Luster, A.D., Leder, P. IP-10, a-C-X-C- chemokine, elicits a potent thymusdependent anti-tumor response in vivo. J. Exp. Med. 178, 1057-1065, 1993.
68. Hermann, F., Schulz, G., Wieser, M., Kolbe, K., Nicolay, U., Noack, M., Lindemann, A., Mertelsmann, R. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am. J Med. 88, 619-624, 1990.
69. Steinmann, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271, 1991.
70. Golumbek, P.T., Azhari, R., Jaffee, E.M., Levitsky, H.l., Lazenby, A., Leong, K., Pardoll, D.M. controlled release, biodegradable cytokine depots; a new approach in cancer vaccine design. Cancer Res. 53, 5841-5844, 1993.
71. Tao, M.H., Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758, 1993.
72. Kwak, L.W., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A., Levy, R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunogiobulin idiotype expressed by their tumors. New Engl. J. Med. 327, 1209-1215, 1992.
73. Lindemann, A., Herrmann, F., Oster, W., Meyenburg, W., Haffner, P., Souza, L., Mertelsmann, R. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74, 2644-2651, 1989.
74. Stoppacciaro, A., Melani, C., Parenza, M., Mastraochio, A., Bassi, C., Baroni, C., Parmiani, G., Colombo, M.P. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation an T cell produced interferon-γ. J. Exp. Med. 178, 151-161, 1993.
75. Walsh, P., Dorner, A., Duke, R.C., Su, L.J., Glode, L.M. Macrophage colonystimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J. Nat. Cancer Inst. 87, 809-816, 1995.
76. Allione, A., Consalvo, M., Nanni, P., Lollini, P.L., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M.P., Dellabona, P., Hock, H., Blankentein, T., Rosenthal, F.M., Gansbacher, B., Bosco, M.C., Mussol, T., Gusella, L., Forni, G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor-α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 87, 6022-6026, 1994.
77. Hock, H., Dorsch, M., Kunzendorf, U., Überla, K., Quin, Z., Diamantstein, T , Blankentein, T. Vaccinations with tumor cells genetically engineered to produce different cytokines, effectivity not superior to a classical adjuvant. Cancer Res, 53, 714-716, 1993.
78. Longo, D.L. New clinical prospects. In "Cytokine-induced tumor immunogenicity. From exogenous molecules to gene therapy". Forni, G, Foa, R., Santoni, A., Frati, L., (eds.) Academic Press Ltd. New York 32, 466-478, 1994.
79. Tepper, R.I., Mulé, J.J. Experimental and clinical studies of cytokine genemodified tumor cells. Hum. Gene Ther. 5, 153-164, 1994.
80. Mertelsmann, R., Lindemann, A., Boehm, T , Brennscheidt, U., Franke, B., Kulmburg, P., Lahn, M., Mackensen, A., Rosenthal, F.M., Veelken, H. Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors. J. Mol. Med. 73, 205-6, 1995.
81. Huang, A.Y.C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965, 1994.
82. Sallusto, F., Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor. J. Exp. Med. 179, 1109-17, 1994.
83. Mackensen, A., Herbst, B., Köhler, G., Wolff-Vorbeck, G., Rosenthal, F.M., Veelken, H., Kulmburg, P., Schaefer, H.E., Mertelsmann, R., Lindemann, A. Delineation of the dendritic cell lineage by generating large numbers of birbeck granule-positive langerhans cells from human peripheral blood progenitor cells in vitro. Blood 86, 2699-2707, 1995.
84. Porgador, A., Gilboa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182, 255-260, 1995.
85. Mukherji, B., Chakraborty, N.G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J.R., Kurtzman, S.K., Ergin, M.T., Ozol, J., Meehan, J., Mauri, F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92, 8078-8082, 1995.
86. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J. Randomised triai of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 343, 1177-1183, 1994.
87. Kast, W.M., Offringa, R., Peters, P.J., Voordouw, A.C., Meloen, R.H., van der Eb, A.J., Melief, C.J. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-14, 1989.
88. Walter, E.A., Greenberg, P.D., Gilbert, M.J., Fich, R.J., Watanabe, K.S., Thomas, D.E., Riddell, S.R. Reconstitution of cellular immunity against cytomegalievirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. New Engl. J. Med. 333, 1038-44, 1995.